{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:04:33Z","timestamp":1769047473420,"version":"3.49.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To find out how bacterial lung infections (BLI) affect the effectiveness of therapy and the rate of pneumonia caused by pneumonia related to checkpoint inhibitors (CIP) in patients with non-small cell lung cancer (NSCLC) who are getting immunotherapy with checkpoint inhibitors (ICIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>507 NSCLC patients who received at least two ICI treatments between June 2020 and December 2022 at the Affiliated Hospital of Kunming University of Science and Technology(AHKUST) were included in a retrospective cohort study. Based on whether there was a concurrent BLI diagnosis from high-resolution CT scans of the chest, the patients were divided into two groups: 238 in the NSCLC with BLI group (NSCLC-BLI group), and 269 in the NSCLC alone group. The collected therapeutic outcome measures included the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and the incidence rate of CIP. We analyzed the effect of BLI on the therapeutic efficacy of ICI treatment and the incidence rate of CIP in NSCLC patients.Inclusion criteria based on NSCLC patients staged I to IV according to the 8th edition of the International Association for Lung Cancer Research (IASLC)<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The NSCLC-BLI group showed superior ORR to the NSCLC group when treated with ICIs. Multifactorial logistic regression and Cox analyses, adjusted for confounders, identified BLI as an independent positive prognostic factor for ORR (HR=0.482, 95%CI: 0.391-0.550; P&amp;lt;0.001) and PFS (HR=0.619; 95%CI: 0.551-0.771; P&amp;lt;0.001). No correlation between BLI and OS was found. Out of 26 cases of CIP, 12 were in the NSCLC-BLI group and 14 in the NSCLC group, with no significant difference in incidence (P=0.145).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>NSCLC patients with BLI receiving ICI treatment show superior ORR and PFS compared to NSCLC alone without an increased CIP risk, positioning BLI as a predictive factor for improved outcomes in NSCLC patients receiving ICIs. However, the study has limitations including its retrospective nature and lacking data on BLI bacteria types and levels, which could influence therapy outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1257638","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T06:01:30Z","timestamp":1693375290000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["The impact of concurrent bacterial lung infection on immunotherapy in patients with non-small cell lung cancer: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiang","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanwei","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangzhu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1183\/2312508X.10020821","article-title":"Antibiotics for lung disease and cancer","volume":"98","author":"Arcadu","year":"2022","journal-title":"Lung Dis. Cancer"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1988403","DOI":"10.1080\/2162402X.2021.1988403","article-title":"Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer","volume":"10","author":"Boesch","year":"2021","journal-title":"Oncoimmunology"},{"key":"B3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41385-022-00529-4","article-title":"Staphylococcus aureus specific lung resident memory CD4+ Th1 cells attenuate the severity of influenza virus induced secondary bacterial pneumonia","volume":"15","author":"Braverman","year":"2022","journal-title":"Mucosal Immunol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"9394","DOI":"10.3390\/ijms22179394","article-title":"Links between infections, lung cancer, and the immune system","volume":"22","author":"Budisan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B5","first-page":"997","article-title":"Risk factors for the development of hepatocellular carcinoma in Chengdu: a prospective cohort study","volume":"26","author":"Cao","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B6","first-page":"221","article-title":"Impact of sleep status on lung adenocarcinoma risk: a prospective cohort study","volume":"26","author":"Cao","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B7","first-page":"776","article-title":"Lung cancer screening study from a smoking population in Kunming","volume":"26","author":"Cao","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B8","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.7150\/jca.50802","article-title":"A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological Malignancy patients receiving chemotherapy","volume":"12","author":"Chen","year":"2021","journal-title":"J. Cancer"},{"key":"B9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jitc-2021-002421","article-title":"Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy","volume":"9","author":"Cortellini","year":"2021","journal-title":"J. Immunother Cancer."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.annonc.2021.08.1744","article-title":"Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy","volume":"32","author":"Cortellini","year":"2021","journal-title":"Ann. Oncol."},{"key":"B11","first-page":"3375","article-title":"Risk factors for postoperative pulmonary infection in patients with non-small cell lung cancer: analysis based on regression models and construction of a nomogram prediction model","volume":"15","author":"Ding","year":"2023","journal-title":"Am. J. Trans. Res."},{"key":"B12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41416-020-0986-4","article-title":"Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper","volume":"123","author":"Gomes","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/2326-6066.CIR-20-0196","article-title":"The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non\u2013small cell lung cancer","volume":"8","author":"Hakozaki","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"B14","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/jitc-2020-000807","article-title":"Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma","volume":"8","author":"He","year":"2020","journal-title":"J. ImmunoTher Cancer."},{"key":"B16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/keab586","article-title":"Clinical role of bronchoalveolar lavage in dermatomyositis-associated interstitial lung disease","volume":"61","author":"He","year":"2022","journal-title":"Rheumatology"},{"key":"B17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40487-021-00171-3","article-title":"Response to PD-1-based immunotherapy for non-small cell lung cancer altered by gut microbiota","volume":"9","author":"He","year":"2021","journal-title":"Oncol. Ther."},{"key":"B18","first-page":"339","article-title":"What is the impact of ITG\u03b28 on NSCLC: A systematic study","volume":"2022","author":"Jin","year":"2022","journal-title":"J. Healthcare Eng."},{"key":"B19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/biomedicines8090349","article-title":"Lung microbiome differentially impacts survival of patients with non-small cell lung cancer depending on tumor stroma phenotype","volume":"8","author":"Kovaleva","year":"2020","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4110\/in.2020.20.e6","article-title":"IL-17-producing cells in tumor immunity: friends or foes","volume":"20","author":"Kuen","year":"2020","journal-title":"Immune Network"},{"key":"B21","article-title":"Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/cancers12061619","article-title":"Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer","volume":"12","author":"Moik","year":"2020","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12885-022-09210-2","article-title":"Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer","volume":"22","author":"Nyein","year":"2022","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3390\/v13091725","article-title":"Viral and bacterial co-infections in the lungs: dangerous liaisons","volume":"13","author":"Oliva","year":"2021","journal-title":"Viruses"},{"key":"B25","doi-asserted-by":"crossref","first-page":"174284","DOI":"10.1016\/j.ejphar.2021.174284","article-title":"Concomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: a pharmacodynamics perspective","volume":"906","author":"Prasetya","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B26","first-page":"1187","article-title":"Mechanisms of p2x7 receptor involvement in pain regulation: a literature review","volume":"38","author":"Qiang","year":"2022","journal-title":"Acta Med. Mediterr."},{"key":"B27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic Malignancies: review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B28","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3390\/curroncol30020181","article-title":"Immunotherapy for metastatic non-small cell lung cancer: therapeutic advances and biomarkers","volume":"30","author":"Russano","year":"2023","journal-title":"Curr. Oncol."},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1024224","article-title":"Innate immune function during antineoplastic treatment is associated with 12-months survival in non-small cell lung cancer","volume":"13","author":"Ryssel","year":"2022","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1047610","article-title":"PD-1\/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejca.2022.06.002","article-title":"Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade","volume":"172","author":"Takada","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.688625","article-title":"The role of tumor inflammatory micro-environment in lung cancer","volume":"12","author":"Tan","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2022.216021","article-title":"Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer","volume":"554","author":"Tang","year":"2023","journal-title":"Cancer Lett."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2147\/IDR.S173456","article-title":"Epidemiology of and risk factors for infection with extended-spectrum \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae: results of a double case-control study","author":"Tian","year":"2018","journal-title":"Infection Drug Resistance"},{"key":"B36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/antibiotics12010140","article-title":"The role of the respiratory microbiome in the pathogenesis of aspiration pneumonia: Implications for diagnosis and potential therapeutic choices","volume":"12","author":"Vallianou","year":"2023","journal-title":"Antibiotics"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.892401","article-title":"Analysis of gut microbiota signature and microbe-disease progression associations in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy","volume":"12","author":"Xi","year":"2022","journal-title":"Front. Cell. Infection Microbiol."},{"key":"B38","article-title":"Case report: Nintedanib for pembrolizumab-related pneumonitis in a patient with non-small cell lung cancer","volume":"11","author":"Xie","year":"2021","journal-title":"Front. Oncol."},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.949745","article-title":"Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and pd-1\/pd-l1 immunotherapy","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"crossref","first-page":"68809","DOI":"10.1007\/s11356-023-27053-7","article-title":"Physical activity mitigates the influence of blood cadmium on memory function: a cross-sectional analysis in US elderly population","volume":"30","author":"You","year":"2023","journal-title":"Environ. Sci. Pollut. Res."},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1192777","article-title":"A novel T-cell exhaustion-related feature can accurately predict the prognosis of OC patients","volume":"14","author":"Yuan","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B42","first-page":"992","article-title":"Intratumoral microbiota impacts the first-line treatment efficacy and survival in non-small cell lung cancer patients free of lung infection","volume":"2022","author":"Zhang","year":"2022","journal-title":"J. Healthcare Eng."},{"key":"B43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/imt-2020-0226","article-title":"Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations","volume":"13","author":"Zullo","year":"2021","journal-title":"Immunotherapy"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1257638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T06:01:58Z","timestamp":1693375318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1257638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":43,"alternative-id":["10.3389\/fcimb.2023.1257638"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1257638","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"article-number":"1257638"}}